Entasis Therapeutics Holdings Inc (ETTX)

Etorro trading 970x250
Entasis Therapeutics Holdings Inc (ETTX) Logo

About Entasis Therapeutics Holdings Inc

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts. Address: 35 Gatehouse Drive, Waltham, MA, United States, 02451

Entasis Therapeutics Holdings Inc News and around…

Latest news about Entasis Therapeutics Holdings Inc (ETTX) common stock and company :

Over $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are Buying
14 Jul, 2022 FinancialContent

US producer prices are likely to rise 0.8% on the month in June to match the previous month’s growth. Investors, meanwhile, ...

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
08 Jul, 2022 FinancialContent

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
09 Jun, 2022 Yahoo! Finance

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treat

Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
03 Jun, 2022 FinancialContent

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeutics Holdings Inc. (“Entasis”) (NASDAQ: ETTX) breached their fiduciary duties to its shareholders in approving a buyout with Innoviva, Inc. (“Innoviva”) (NASDAQ: INVA) for inadequate consideration. If you are an Entasis shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
25 May, 2022 Yahoo! Finance

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
24 May, 2022 Yahoo! Finance

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

AstraZeneca spinout, based in Waltham, acquired at 60% premium
24 May, 2022 Yahoo! Finance

Entasis Therapeutics, an antibiotics developer that spun out of AstraZeneca plc in 2015, has been acquired by its majority shareholder, California's Innoviva Inc.

58 Biggest Movers From Yesterday
24 May, 2022 FinancialContent

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its ...

ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc
23 May, 2022 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeutics Holdings Inc. (NasdaqGM: ETTX) to Innoviva, Inc. (NasdaqGS: INVA). Under the terms of the proposed transaction, shareholders of Entasis will receive only $2.20 in cash for each share of Entasis that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to Shareholders
23 May, 2022 FinancialContent

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) to Innoviva, Inc. for $2.20 per share in cash is fair to Entasis shareholders.

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
23 May, 2022 FinancialContent

Innoviva Inc(NASDAQ: INVA) hasagreed to acquireEntasis Therapeutics Holdings Inc(NASDAQ: ETTX) at$2.20 ...

Innoviva to Acquire Entasis Therapeutics
23 May, 2022 FinancialContent

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis’ equity at $113 million on a fully diluted basis. The transaction has been unanimously approved by the Innoviva and Entasis Boards of Directors.

Antibiotic resistance efforts get a boost as CARB-X gets $370M
19 May, 2022 Yahoo! Finance

Kevin Outterson has spent the better part of the last year in conversations with CARB-X's previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.

Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
17 May, 2022 Yahoo! Finance

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference, held this week from May 16-18, 2022, in San Francisco, California. The poster presentation―P628 Sulbactam-Durlobactam (SUL-

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
06 May, 2022 FinancialContent

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of ...

Entasis Therapeutics Hldg: Q1 Earnings Insights
27 Apr, 2022 FinancialContent

Entasis Therapeutics Hldg (NASDAQ:ETTX) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 ...

Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
27 Apr, 2022 Yahoo! Finance

Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conferenceSUL-DUR NDA submission on track for mid-2022Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announce

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Apr, 2022 FinancialContent

Gainers Agile Therapeutics (NASDAQ:AGRX) shares increased by 45.7% to $0.2 during Tuesday's pre-market session. The ...

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
26 Apr, 2022 Yahoo! Finance

Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line data from the company’s pivotal Phase 3 ATTACK trial was presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) an

Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
18 Apr, 2022 Yahoo! Finance

WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, 2022 in Lisbon, Portugal. Among

Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
16 Mar, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! The post Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
16 Mar, 2022 FinancialContent

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, ...

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
08 Mar, 2022 FinancialContent

Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to ...

Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2022
04 Mar, 2022 FinancialContent

Upgrades According to Susquehanna, the prior rating for Knight-Swift Transportation Holdings Inc (NYSE:KNX) was changed from Neutral to ...

Recap: Entasis Therapeutics Q4 Earnings
03 Mar, 2022 FinancialContent

Entasis Therapeutics Hldg (NASDAQ:ETTX) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's ...

Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
03 Mar, 2022 Yahoo! Finance

Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023Entasis’ pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal NatureReceipt of acquisition proposal from existing majority shareholder Innoviva, Inc. WALTHAM, Mass., March 03, 2022 (GLOB

54 Biggest Movers From Yesterday
03 Feb, 2022 FinancialContent

Gainers MDJM Ltd (NASDAQ: MDJH) shares surged 35.6% to close at $2.44 on Wednesday after gaining 10% on Tuesday. GWG Holdings, ...

Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
02 Feb, 2022 Yahoo! Finance

WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration o

12 Health Care Stocks Moving In Wednesday's Intraday Session
02 Feb, 2022 FinancialContent

Gainers Epizyme (NASDAQ:EPZM) stock increased by 14.2% to $1.41 during Wednesday's regular session. As of 12:30 EST, ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
02 Feb, 2022 FinancialContent

Gainers Pharming (NASDAQ:PHAR) shares increased by 15.8% to $10.21 during Wednesday's pre-market session. The ...

Entasis Therapeutics Holdings Inc (ETTX) is a NASDAQ Common Stock listed in , ,

970x250